# The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

> **NCT05540327** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 379 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** M5049 low dose
- **DRUG:** M5049 medium dose
- **DRUG:** M5049 high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05540327
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-16
- **Primary completion:** 2028-08-12
- **Final completion:** 2028-08-12
- **Target enrollment:** 379 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05540327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05540327, "The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05540327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*